Dong-A ST Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1932-01-01
- Employees
- 1.6K
- Market Cap
- -
- Website
- http://www.donga-st.com
A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT03646721
- Locations
- 🇺🇸
Clinical Site, Chula Vista, California, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸High Point Clinical Trials Center, High Point, North Carolina, United States
A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder
- Conditions
- Interventions
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 306
- Registration Number
- NCT03566134
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT03521713
- Locations
- 🇹🇷
Gazi University Medical Faculty, Ankara, Turkey
A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 143
- Registration Number
- NCT03343145
- Locations
- 🇮🇩
RSUP Dr. Hasan Sadikin, Bandung, Indonesia
Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis
- Conditions
- Interventions
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT03280927
- Locations
- 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of
Pharmacokinetics and Safety/Tolerability Profiles of DA-5206 Versus Talion® Under Fasting and Fed States in Healthy Male Subjects
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03200496
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Safety and Efficacy of DA-9805 for Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT03189563
- Locations
- 🇺🇸
HealthPartners Institute, Bloomington, Minnesota, United States
A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03061981
- Locations
- 🇺🇸
Early Phase Clinical Unit, Baltimore, Maryland, United States
Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 207
- Registration Number
- NCT02974504
- Locations
- 🇰🇷
Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of
Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 123
- Registration Number
- NCT02967939
- Locations
- 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of